

DEPARTMENT OF HEALTH

Taking Aim at Cancer in Louisiana Summit: May 11, 2018 Pre-Read Document **Objective:** To provide an overview of the market environment, target interventions and collaboration structure as context for the May 11th Taking Aim at Cancer in Louisiana Summit



Theory of the Market



Intervention Areas



Collaboration Framework and Roadmap



Situation	Louisiana has the fourth highest cancer mortality rate in the nation, with more than 175 people dying from cancer every week. The State experiences significant disparities across populations, more late stage diagnoses than expected, and variations in treatment and costs beyond what can be explained by the underlying conditions.
Impetus for Change	The recent Medicaid expansion and other commercial and Medicare market factors present an opportunity for a Louisiana-wide initiative to improve cancer outcomes. Louisiana's Health Secretary Rebekah Gee, MD has convened a committed group of State officials, payers, providers, researchers and other stakeholders to find ways to make this possibility a reality.
Approaches to Change	This initiative will support the adoption and spread of best practices that will improve cancer outcomes in the state.

Source: Louisiana Comprehensive Cancer Control Plan 2017-2021

THEORY OF THE MARKET



Louisiana cancer incidence and mortality rates exceed U.S. rates by 7% and 13% respectively, with a handful of cancers causing a disproportionate share of the suffering.

	Five Leading Cancer-Related Causes of Death in Louisiana						
Average Annual Cases & Incidence per 100,000 (Age-Adjusted)			Average Annual # Deaths & Mortality per 100,000 (Age-Adjusted)				
Louisiana (2011-2015) ¹ U.S. (2010-2014) ² Louis		Louisiana (2	2011-2015) ¹	U.S. (2011-2015) ²			
Cancer Type	Average Annual # Cases	Incidence Rate	Incidence Rate	Cancer Type	Average Annual # Deaths	Mortality Rate	Mortality Rate
Lung	3,515	68.8	61.2	Lung	2,701	53.6	43.4
Breast (female)	3,340	124.1	123.5	Breast (female)	651	23.7	20.9
Prostate	3,387	137.4	114.8	Prostate	412	21.6	19.5
Colorectal	2,347	46.5	39.8	Colorectal	874	17.5	14.5
Pancreas	725	14.4	12.5	Pancreas	653	13.1	10.9
All Cancer	22,506	475.9	443.6	All Cancer	9,362	187.8	163.5


By reducing Louisiana's cancer mortality rates to the national average, <u>1,500 fewer</u> Louisianans would die each year from cancer.

Source: Louisiana Comprehensive Cancer Control Plan 2017-2021 ¹Louisiana Tumor Registry. ²NIH/CDC State Health Facts



5

Persistent and large racial disparities exist among the five most common cancers.




Inpatient cancer care in Louisiana is concentrated; eight of the State's health systems provide over 80% of inpatient cancer care.

Health System	Health System Facility Parishes		% of Total
Ochsner	Since Orleans, St. Tammany, Jefferson, East Baton Rouge, Terrebonne, St. Charles, Lafourche, Rapides, Caddo, Calcasieu, Natchitoches, Red River, Evangeline, Ouachita		32%
Franciscan Missionaries of Our Lady Health System	East Baton Rouge, Lafayette, Ouachita, Ascension, Washington 5,505		13%
НСА	Orleans, Rapides, St. Tammany, Lafayette, Jefferson		12%
LCMC	Orleans, Jefferson	4,905	8%
Willis Knighton Health Caddo, Bossier		3,470	7%
Lafayette General Health	vette General Health Lafayette, Acadia, St. Martin, St. Landry		5%
Baton Rouge General	East Baton Rouge	2,004	4%
St. Tammany	St. Tammany St. Tammany		3%
	Cancer Discharges	33,443	84%

Cancer Care Variation

There are significant variations in cost per patient across Louisiana parishes.





	Highest Cost by Parish of Residence			
	# Claimants Allowed Amounts Allowed per Claimant		Allowed per Claimant	
East Carroll	56	\$1,039,521	\$18,563	
West Carroll	81	\$1,166,407	\$14,400	
Caldwell	96	\$1,122,622	\$11,694	
Madison	94	\$1,090,965	\$11,606	
Lincoln	420	\$4,769,164	\$11,355	
Union	183	\$2,023,975	\$11,060	
Morehouse	192	\$2,012,722	\$10,483	
Catahoula	120	\$1,181,594	\$9,847	
Ouachita	1,067 \$10,261,723 \$9,617		\$9,617	

	Lowest Cost by Parish of Residence			
	# Claimants Allowed Amounts		Allowed per Claimant	
Terrebonne	788	\$3,027,748	\$ 3,842	
Saint Bernard	218	\$794,822	\$ 3,646	
Beauregard	316	\$1,039,677	\$ 3,290	
Assumption	267	\$855,280	\$ 3,203	
Saint James	203	\$629,898	\$ 3,103	
Allen	205	\$620,572	\$ 3,027	
Lafourche	1,050	\$3,133,745	\$ 2,985	
Calcasieu	1,934	\$5,168,357	\$ 2,672	
Cameron	94	\$242,700	\$ 2,582	

manatt

Sources: Commercial claims analysis

Ten payers provide coverage for the vast majority of residents with cancer in the State.

		Payer Type			
Payer		All Discharges	Commercial	Medicaid	Medicare
MEDICARE FFS		13,242	0	0	13,242
BLUE CROSS BLUE SHIELD		4,699	4,683	0	16
HUMANA		4,693	2,876	0	1,817
MEDICAID FFS		2,854	0	2,772	82
UNITED		1,869	1350	448	71
PEOPLES		1,725	839	0	886
AETNA		644	417	177	50
LOUISIANA HEALTHCARE CONNECTIONS (CENTENE)		557	1	556	0
CIGNA		376	376	0	0
AMERIGROUP		290	0	290	0
Total Cancer Discharges in Loui	isiana*:	41,399	12,451	4,653	16,554
<mark>% c</mark>	of Total	75%	85%	91%	98%

Inpatient Discharges for Cancer Care by Payer in 2016


The Big Picture

Theory of Market	Implications
A handful of cancers cause a disproportionate share of mortality in Louisiana.	Initiatives should focus on select cancers.
Persistent and large racial disparities in terms of incidence, mortality and stage at diagnosis exist across all major cancers.	Any statewide strategy must address disparities.
Limited access to care put Louisianans at increased risk of later stage diagnoses.	Interventions must improve residents' access to prevention, screening and treatment services.
Medicaid expansion has yielded improved access to screenings and treatment.	Further use of payment and regulatory levers can support better cancer outcomes.
The majority of inpatient cancer care in Louisiana is delivered in eight health systems.	With broad health system participation in a "big tent" initiative, we can reach a high percent of residents.
Significant variation in cost per case exists across parishes.	Establishing standards of care could help reduce outliers and cost, and improve outcomes.
Ten payers cover the vast majority of Louisiana residents with cancer.	Coordination across Louisiana's biggest payers can align incentives to drive meaningful improvement in cancer care.

INTERVENTION RECOMMENDATIONS




We recommend focusing initially on a small number of interventions that are achievable and can demonstrate improvements and value for Louisiana residents, payers and providers.



Colorectal Cancer Screening Louisiana's Current State

Low colorectal cancer screening rates result in more late stage diagnoses, higher mortality and higher cost.



Louisiana Tumor Registry, Louisiana Cancer Prevention & Control Program;
 Louisiana Comprehensive Cancer Control Plan 2017-2021,
 2004-2010, American Cancer Society: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
 Medicare spending, in: Styperek, A.; Kimball, A.B. Malignant Melanoma: The Implications of Cost for Stakeholder Innovation. Am. J. Pharm. Benef. 2012, 4, 66–76.

13


Colorectal Cancer Screening Intervention Concept

This intervention would focus on reducing mortality associated with colorectal cancer via improved screening.

Clinical Initiatives	 Expand mobile medical clinics' geographic coverage, using FIT kits and colonoscopies Establish screening programs that are culturally competent in coordination with community and faith-based organizations to meet the needs of diverse communities across the state Conduct educational campaigns targeting at-risk population including French-Acadian community that encourage at-risk individuals to get screened Develop navigator programs to connect individuals with screening programs and appropriate follow-up care as needed; potentially as a centralized resource to work with health systems and primary care providers in target regions to identify and recruit target patients and follow-up with patients on outstanding screening samples and results Develop screening and follow-up treatment guidelines and protocols Evaluate the provider network to identify areas where access to GI is lacking
Incentives and Support	 Establish incentives for providers and patients to participate in screening (e.g., wellness incentives, zero out of pocket for screening) Fund public education and outreach targeted to at-risk populations to promote screening Collaborate with community and faith-based organizations
Measurement & Reporting	 Set screening rate targets Measure and report screening rates at provider, health plan, parish and statewide levels

Breast Cancer Treatment Louisiana's Current State

Preliminary analysis of Louisiana Medicaid claims shows a 2-3x higher outlier rate for breast cancer treatment costs as compared to that of other cancers, and higher variability in treatment patterns of breast cancer.



	Per Patient Allowed Costs By Stage for Commercially Insured Breast Cancer Patients			
Stage at Dx	0–6 Months Post-Diagnosis	0–12 Months Post-Diagnosis	0–24 Months Post-Diagnosis	
0	\$48,477	\$60,637	\$71,909	
I/II	\$61,621	\$82,121	\$97,066	
III	\$84,481	\$129,387	\$159,442	
IV	\$89,463	\$134,682	\$182,655	

This intervention would focus on improving outcomes and reducing treatment variation.

Clinical Initiatives	 Develop community standard of care for breast cancer treatment Engage providers and payers in guideline and pathway development and updates, and review provider compliance with care standards Utilize mobile mammography vans and telehealth to support treatment in coordination with rural PCPs (e.g., Project ECHO) Explore facilitation of clinical trial access (inducements and barriers) – may include cross-institutional contracts, streamlined IRB process and engagement of pharmaceutical companies Increase community-based clinical trial accruals
Incentives and Support	 Define care bundle based on episodes of care (including surgery, radiation oncology and medical oncology) and/or establish incentives for adopting and using guidelines and protocols* Explore criteria for establishing Centers of Excellence or Networks of Excellence based on process and outcomes measures
Measurement & Reporting	 Leverage tumor registry, claims data and other sources to measure access to care by payer and outcomes (unplanned care, patient reported outcomes, relapse) Report process (guideline adoption, bundle adoption) and outcome measures at the provider, health plan and statewide level

*Payers would negotiate and establish bundle and/or incentive reimbursement directly with providers, not through the collaborative

COLLABORATION FRAMEWORK AND ROADMAP




We have an opportunity to work together to improve cancer outcomes in Louisiana.

Stakeholders	Value of Collaboration
Patients	 ✓ Better outcomes ✓ Improved access to prevention, screening and standard of care treatment for patients with cancer
Providers & Health Systems	 ✓ Healthier patients ✓ Opportunity to define new approaches to care ✓ Transparency into how clinical practices compare to standards of care ✓ Standardized approach to cost/quality incentives ✓ Financial and logistic support for screenings
Payers	 ✓ Healthier members ✓ More efficient healthcare spending due to increased screening & earlier treatment ✓ Improved member experience and satisfaction
State of Louisiana	 Healthier population and workforce More efficient use of general funds and healthcare spending due to increased screening & earlier treatment



Cancer Collaborative Care – Proposed Structure



The committees should be comprised of representatives from key sectors to ensure the collaborative has the breadth and depth of expertise to fulfill its charters.

Sector	Expected Role in Collaborative
State Government Agency	 Contribute patient- and population-level data to inform decision-making Contribute to collaborative's sustainability
Provider	 Contribute patient- and population-level data and findings to inform root cause and impact analyses Provide feedback, evaluate and recommend potential clinical priorities and practices Contribute to collaboration's sustainability
Payer	 Contribute patient- and population-level data to inform root case and impact analyses Evaluate and recommend clinical priority areas and potential payment arrangements Contribute to collaboration's sustainability
Education/Research Institution	 Contribute patient- and population-level data and findings to inform root cause and impact analyses Evaluate and recommend potential clinical priorities, practices and performance metrics Identify opportunities for research and clinical trials recruitment
State Association	 Represent diversity of Louisiana providers' perspectives related to the collaborative' s interests (e.g., administrative burden) Contribute relevant data
Patient Advocate/ Community-based Organization	Keep patient outcomes and experience central to the mission of the collaboration
Others (e.g., policy experts, business)	Contribute unique subject matter expertise

Proposed Roadmap

The committees will launch initial interventions in the first year, refine/enhance approaches in the second, and demonstrate value and results to support longer term planning in the third.

	Year 0	Year 1	> Year 2	Year 3
Executive Committee	 Define operating model Constitute committees and charters Identify and retain Director Define initial targets & set annual goals 	Select year two interventionsFundraising	Select year three interventionsFundraising	 Direct development of next three-year strategic plan Select new fundraising target
Clinical Committee	Assess and define initial priorities including target conditions and associated interventions	 Define and implement guidelines and interventions Define and implement program elements Recruit sites/physician champions as needed 	 Refine interventions and guidelines Recommend year 2+ priority areas and interventions 	 Contribute to evaluation of clinical intervention impact Recommend guidelines and interventions to support strategy
Policy Committee	Conduct economic impact analysisAssess cost of care variation	 Convene stakeholders to define and prioritize intervention recommendations Define short-term policy and programmatic changes that are needed to promote better access, reduced cost, and higher quality 	Implement short-term policy and programmatic changes	Contribute to evaluation of impact of short-term policy and programmatic changes
Data & Reporting Committee	 Assess mortality rate and incidence Identify variation in care, treatment patterns, cost and utilization outliers Define service provision Define disparity parameters 	 Assess variations, high cost clinical areas Define measures (clinical, financial, access, experience) Establish baseline measure and reporting Begin any new data collection for baseline 	 Continue to refine registry, claims, and other data collection elements Measure & publish results (i.e. baseline Y1 outcomes) 	Lead evaluation of interventions and generate reports
Staff	Director recruited and on-boarded	 Facilitate committees, selection and implementation of interventions Facilitate fundraising 	 Facilitate committees, selection and implementation of interventions Facilitate fundraising 	 Facilitate committees, development of three-year strategic plan Facilitate fundraising